Canada markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5180+0.0054 (+1.05%)
At close: 03:59PM EST
0.5300 +0.01 (+2.32%)
After hours: 08:00PM EST

Longeveron Inc.

Life Science and Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
305 909 0840

Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Ms. Joshua Michael Hare FACC, M.D.Co-Founder, Chief Science Officer & Chairman88kN/A1963
Mr. Paul T. Lehr J.D.International Executive Director, General Counsel & Secretary448.26kN/A1968
Mr. Mohamed Wa'el Ahmed HashadCEO & DirectorN/AN/A1962
Ms. Lisa A. LocklearPrincipal Financial Officer & Accounting Officer, Executive VP and CFON/AN/A1961
Dr. Dan Gincel Ph.D.Senior Vice President of Strategic Collaborations & Scientific AffairsN/AN/A1971
Dr. Nataliya Agafonova M.D.Chief Medical OfficerN/AN/A1969
Ms. Elly RyuVP & Corporate ControllerN/AN/A1982
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Corporate Governance

Longeveron Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.